The Centre for Process Innovation (CPI) is partnering with Gyroscope Therapeutics, Freeline Therapeutics and NHS Blood and Transplant’s Clinical Biotechnology Centre to develop and design a manufacturing platform to produce novel (adeno-associated virus) AAV gene therapies.
The consortium has been awarded £1.1m funding by Innovate UK over a period of two years.
The funding is a great endorsement of the work currently being undertaken at Gyroscope and Freeline and will help the companies as they continue to develop a shared scalable suspension platform for cost-effective manufacture of novel AAV gene therapies.
Establishing a fully-integrated AAV gene therapy platform is key to ensuring rapid and secure manufacture of clinical supplies and commercial product.
Ultimately, the successful outcome will address a significant manufacturing challenge for gene therapies, strengthen the UK position as a leader in scientific innovation, offer scope for investment and employment into UK pharmaceutical manufacturing and bring healthcare benefits to patients.
Gyroscope and Freeline were complimented on the application, which was viewed as a “very high-quality application” and “a very good application from two therapeutic companies coming together.”